UNSPSC 51182214: Misoprostol

This classification denotes a prostaglandin analogue and cytoprotective agent and anti-ulcer agent with the molecular formula C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0E43V0BB57, chemically known as prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13e)-(+-)- but generally known as misoprostol, which bears US NIH Compound Identifier 5282381. European Medicines Agency schedules Misoprostol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08998MIG.

UNSPSC 51182214 Misoprostol, a Commodity code, encompasses pharmaceutical products sourced through state and local cooperative purchasing frameworks, with recent activity centered on multi-state generic drug supply agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently issued an RFP for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. State and local health agencies, correctional facilities, and institutional healthcare systems procure pharmaceutical inventory through these cooperative vehicles, which leverage aggregated purchasing volume to secure pricing concessions from manufacturers. Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and carry commercial general liability insurance of $5,000,000 per occurrence plus professional liability and network security coverage. Evaluation emphasizes price competitiveness (75 percent weight) and administrative compliance, with awarded vendors paying a 3 percent administrative fee on all purchases.

MMCAP's RFP issued January 20, 2026 with proposals due March 26, 2026 represents the primary recent opportunity under this code. The solicitation targets manufacturers able to supply comprehensive pharmaceutical product lines with specific National Drug Codes (NDC) and flexible pricing structures (flat price, net price formats, or WAC-minus models), with contract term of two years for new responders and optional extensions at MMCAP's discretion. Products must be available in the marketplace by May 15, 2026, with awarded agreements effective July 1, 2026 through June 30, 2028 for incumbent vendors. The RFP does not disclose specific award values or budget ranges, but MMCAP reserves multi-award rights based on therapeutic considerations and member-specific needs, suggesting distributed awards across multiple manufacturers serving different product categories or regional preferences.